Aclaris Therapeutics, Inc. (LON:0H8T)

Market Cap	143.52M
Revenue (ttm)	12.25M
Net Income (ttm)	-98.28M
Shares Out	n/a
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,568
Average Volume	7,873
Open	2.035
Previous Close	2.025
Day's Range	1.940 - 2.040
52-Week Range	1.058 - 5.150
Beta	n/a
RSI	50.29
Earnings Date	Nov 6, 2025

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 64
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H8T

Financial Performance

In 2024, Aclaris Therapeutics's revenue was $18.72 million, a decrease of -40.09% compared to the previous year's $31.25 million. Losses were -$132.07 million, 49.3% more than in 2023.

Financial numbers in USD